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Abstract
Objective: Candida parapsilosis is an infrequent isolate on vaginal cultures; its role as a vaginal pathogen remains unstudied.
This retrospective study of women with positive culture for C. parapsilosis sought to characterize the signiﬁcance of this
ﬁnding and its response to antifungal therapy.
Methods: From February 2001 to August 2002, we identiﬁed all individuals with positive fungal isolates among a
population of women with chronic vulvovaginal symptoms. Charts of women with C. parapsilosis cultures were reviewed with
regard to patient demographics, clinical presentation and therapeutic response. Mycological cure, deﬁned as a negative
fungal culture at the next ofﬁce visit, and clinical cure, i.e. symptom resolution, were determined for each subject.
Results: A total of 582 women had positive vaginal cultures for 635 isolates, of which 54 (8.5%) were C. parapsilosis. The
charts of 51 subjects with C. parapsilosis were available for review and follow-up cultures and clinical information were
available for 39 (76.5%). Microscopy was positive in 9 (17.6%). Antifungal treatment resulted in mycological cure in 17/19
patients with ﬂuconazole, 7/7 with butoconazole, 6/6 with boric acid, 1/1 with miconazole and occurred spontaneously in 6/
7: 24/37 (64.9%) patients with a mycological cure experienced clinical cure.
Conclusions: Although C. parapsilosis is often a cause of vaginal symptoms, it seems to respond to a variety of antifungal
agents and may even be a transient vaginal colonizer.
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Introduction
Vaginitis is the most common reason for patient
visits to obstetrician-gynecologists and accounts for
over 10 million physician ofﬁce visits annually [1].
Among the most common diagnosis in women
presenting with vaginal irritation is vulvovaginal
candidiasis(VVC); 80% to 90% of sporadic, un-
complicated cases of VVC are caused by the species
Candida albicans [2]. However, other species may
be responsible for up to 30% of recurrent VVC
cases [3]. The identiﬁcation of non-C. albicans
species in vulvovaginal infection is important
because some non-C. albicans species are resistant
to the standard azole therapy used to clear the
infection. The most common non-C. albicans
species that have been implicated in recurrent
VVC include Candida glabrata, Candida tropicalis,
Candida krusei, and Saccharomyces cerevisiae.T oa
lesser extent Candida parapsilosis has been identiﬁed
as a vaginal isolate, but little evidence exists to
support its role as a vaginal pathogen; it may simply
represent colonization of the normal vaginal envir-
onment.
The identiﬁcation of non-C. albicans species on
vaginal fungal culture has become more common in
recent years. This may partially be due to the
increased usage of vaginal fungal cultures for
accurate diagnosis of complicated or recurrent
VVC, as recommended by several authors [3, 4].
Others believe that the increase in non-C. albicans
isolates is secondary to the increased use and
availability of over-the-counter antimycotic prepara-
tions [5, 6]. Regardless of the reason, a positive
culture for non-C. albicans yeast species such as C.
parapsilosis from a symptomatic patient may some-
times lead to treatment. However, with the less
common types of yeast, determining whether treat-
ment is appropriate and what it should consist of may
not be clear.
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vaginal fungal culture, and there have been no
studies that look speciﬁcally at its relevance to
symptoms. Because C. parapsilosis produces certain
virulence factors such as acid proteinases, it has been
hypothesized that this organism is a vaginal pathogen
[7] but it remains relatively unstudied as a cause of
VVC. The purpose of this descriptive study was to
determine the prevalence of C. parapsilosis isolates in
our population, to evaluate the symptoms experi-
enced by women with positive vaginal cultures, to
examine the effectiveness of different antifungal
remedies against C. parapsilosis and to determine
whether a negative follow-up culture was associated
with the relief of vaginal complaints. In doing so, our
goal was to determine whether C. parapsilosis
represents a true vaginal pathogen.
Methods
The study population was derived from women
referred by their primary care physicians for medical
treatment of chronic vulvovaginal complaints at an
outpatient vaginitis referral center. From February
2001 to August 2002, all individuals with positive
vaginal fungal isolates were identiﬁed using ofﬁce
ﬂowsheets maintained to track and notify patients of
their results. All women with a positive culture for C.
parapsilosis were selected for retrospective chart
review. Data regarding demographics, medical his-
tory, symptom history, and treatment were obtained
from standardized patient chart notes. Follow-up
information was obtained from additional chart
entries. The Institutional Review Board at Thomas
Jefferson University Hospital approved the study
protocol.
Two clinicians, both specialized in the treatment
of chronic vulvovaginal complaints, collected data
and examined all subjects throughout the study
period. Saline wet-mount preparations, 10% potas-
sium hydroxide (KOH) preparations, and vaginal pH
determinations were obtained routinely for women
seen at the center. Saline and KOH preparations
were performed by spreading vaginal secretion
samples on separate slides, adding the appropriate
solutions, and then evaluating with both low- and
high-power microscopy for the presence of fungal
elements, altered vaginal ﬂora, clue cells, trichomo-
nads, vaginal cytology and white blood cells. Sterile
culture swabs were used to sample the external
vulvar skin and lateral vaginal sidewalls on speculum
exam for yeast cultures. Three laboratories analyzed
vaginal swabs for fungal isolates. The patient’s
insurance carrier dictated which laboratory site was
used to analyze the fungal swab.
The Thomas Jefferson University laboratory (Phi-
ladelphia, PA, USA) identiﬁed yeast isolates by ﬁrst
plating vaginal swabs onto CHROMagar plates. If
growth was seen on the CHROMagar, then a saline
wet mount was prepared to conﬁrm the presence of
yeast species. Germ tube-positive species were
identiﬁed as C. albicans. Germ tube-negative colo-
nies were further speciated using the Rapid ID
System (Remel, Lenexa, KS, USA). This presump-
tive diagnosis was simultaneously conﬁrmed using
cornmeal agar and urea tubes. Quest Diagnostics
Laboratory (Philadelphia, PA, USA) used inhibitory
mold agar for the initial plating of vaginal swabs.
Germ tube-negative colonies were further isolated
using Sabouraud agar. Pure colonies were then
speciated using API 20 C (BioMerieux Vitek Inc.,
Hazelwood, MO, USA), a carbohydrate assimilation
test, in conjunction with morphology testing for
proper identiﬁcation. Laboratory Corporation of
America (New Castle, DE, USA) initially seeded
Sabouraud-dextrose agar and Mycosel agar with
vaginal swabs. Germ tube-positive species were
conﬁrmed as C. albicans by the concurrent formation
of chlamydospores in cornmeal agar. Germ tube-
negative colonies were further speciated using the
YBC card (BioMerieux Vitek, Hazelwood, MO,
USA). Conﬁrmatory testing was performed using
the API 20 C system.
Symptoms were documented at the index visit and
at the follow-up visit. Follow-up visits occurred
between 1 and 4 months after the initial C.
parapsilosis culture. Intervening treatments and com-
pliance with treatment were reviewed, as well as
change in vaginal symptoms. A clinical cure was
deﬁned as complete resolution of the symptoms
noted at the time of the index visit. Mycological cure
was deﬁned as resolution of C. parapsilosis on follow-
up culture. Cases were documented as a sponta-
neous mycological cure if the follow-up culture did
not grow C. parapsilosis and antifungal treatment was
never initiated.
Statistical analysis was performed using EpiInfo
2002 (CDC, Atlanta, GA, USA). Two- tailed chi-
square statistical analysis was carried out using the
Mantel—Haenszel formula. Statistical signiﬁcance
was deﬁned as a p value 50.05.
Results
A total of 582 women had positive vaginal cultures
for 635 isolates; 609 organisms were grown on pure
culture and 13 cultures contained growth of mixed
species. Table I shows the distribution of isolates
among this patient population. Isolates positive for
C. parapsilosis were found in 54 (8.5%) of women, 1
of whom had a culture positive for both C. albicans
and C. parapsilosis. The charts of 51 patients with C.
parapsilosis were available for review, and follow-up
culture and clinical information was available in 39
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were seen for follow-up within 6 weeks of the index
visit.
The median patient age was 46 years (range 19 to
86 years); 49 women (96.1%) were Caucasian and
18 (35.3%) were nulliparous. Of the 21 women
(41.2%) who were menopausal, 19 (90.5%) were
receiving estrogen therapy. Oral contraceptives were
being used by11 (21.6%), and 21 (41.2%) had used
antifungals and 10 (19.6%) had used topical steroids
within 1 month of positive culture. At the time of the
index visit, complaints comprised itching in 27
(53%), burning in 22 (43.1%), abnormal discharge
in 11 (21.6%) and dyspareunia in 16 (31.4%)
women. However, 9 (17.6%) were asymptomatic at
the time of positive culture although microscopy was
also positive, and of these 4 were seen for a follow-up
visit.
In this study, 37 women (72.5%) had associated
vulvovaginal conditions. Of these, the most com-
mon conditions were atrophic vaginitis in 11
(29.7%), irritant dermatitis in 8 (21.6%), lichen
sclerosus in 8 (21.6%) and vulvar vestibulitis in 5
(13.5%). Other diagnoses included vulvodynia,
herpes simplex, recurrent bacterial vaginosis and
desquamative inﬂammatory vaginitis, and 8 women
(21.6%) carried the diagnosis of two vulvovaginal
conditions in addition to C. parapsilosis vaginitis.
Between the index and follow-up visits, the only
change in treatment was the institution of antifungal
therapy.
A variety of antifungal regimens were used in
patients with cultures positive for C. parapsilosis.T h e
treatments included boric acid, 600 mg twice daily
for 2 weeks, buconazole, two vaginal applicator doses
1 week apart, ﬂuconazole, 200 mg twice weekly for 1
month, and miconazole, one applicator nightly for 7
days. The choice of antifungal agent was left to the
discrimination of the clinician. Antifungal treatment
resulted in mycological cure in 17/19 cases with
ﬂuconazole, 7/7 with buconazole, 6/6 with boric acid,
and 1/1 with miconazole. Mycological cure also
occurred spontaneously in 6/7 women, of whom 24/
37 (64.9%) experienced clinical cure. Of those with
associated vulvovaginal conditions, 14/26 women
achieved both mycological and a clinical cures (10
with treatment and 4 without treatment), whereas
10/13 without associated vulvovaginal conditions
achieved both clinical and mycological cures (9 with
treatment and 1 without treatment).
Discussion
More than 80% of VVC cases are caused by the
species C. albicans. In mild cases the organism
responds to a variety of standard azole remedies,
wheeas complicated or recurrent cases respond to
moreaggressivemultiple-doseregimens.Theremain-
ing cases of vaginal candidasis are caused by non-C.
albicans species that appear to have higher minimum
inhibitory concentrations to standard azole therapies
[6]. Additionally, some investigators have questioned
whether some non-C. albicans species cause vulvova-
ginal symptoms at all [7, 8]. Most of these studies
evaluated the non-C. albicans isolates collectively,
without studying symptomatology or the mycotic
response of minor isolates individually. To our
knowledge, this is the largest study that looks
exclusively at the minor isolate Candida parapsilosis,
its prevalence, symptomatology and mycotic re-
sponse.
The prevalence of Candida parapsilosis in our study
was slightly higher (8.5%) than that previously
documented. Other authors report prevalence of
5% or less for C. parapsilosis in symptomatic patients;
however, these studies evaluate prevalence in a much
smaller population than ours [3, 4]. Sood et al.
report a prevalence of 12% in their study of
terconazole for treatment of non-C. albicans vaginitis,
but studied only 28 patients, 3 of whom had C.
parapsilosis isolates [9]. Because this study was
speciﬁcally a study of non-C. albicans cases, the
12% incidence of C. parapsilosis in the series may not
be an accurate reﬂection of the incidence in larger
population of women with complicated VVC. Our
study may over-represent the true prevalence be-
cause of the selection bias of our population. Women
seeking treatment at a vaginitis referral center may be
more likely to have cultures positive for C. para-
psilosis, because cases of uncomplicated candidiasis
are eliminated from a referred population.
The symptoms experienced by women with C.
parapsilosis infection were typical of any vulvovaginal
infection. Complaints included itching (53%), burn-
ing (43.1%), dyspareunia (31.4%) and abnormal
discharge (21.6%). Approximately 20% appeared to
be asymptomatically colonized with C. parapsilosis at
the index visit. Certainly, the reported complaints are
not unique to VVC and could also be attributed to
secondary diagnoses affecting the vulvovaginal area,
which were present in 72.5% of the study population.
Likewise, objective ﬁndings suggestive of candidiasis
Table I. Distribution of yeast isolates.
Species Number Percentage
Candida albicans 457 72.0%
Candida glabrata 74 11.7%
Candida parapsilosis 54 8.5%
Rhodotorula spp. 18 2.8%
Saccharomyces cerevisiae 9 1.4%
Candida lusitaniae 5 0.8%
Other species 18 2.8%
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as only 17.6% of cases demonstrated yeast species on
saline microscopy. In the few subjects with positive
microscopy, the objective ﬁnding was not helpful in
predicting whether the woman would achieve a
mycotic and symptomatic cure with treatment. This
underscores the usefulness of vaginal fungal cultures
for deciphering the diagnostic ambiguity of vulvova-
ginal conditions. Without a positive fungal culture,
the isolate could masquerade as a number of other
conditions, eluding appropriate treatment.
When pretreatment and post-treatment symptoms
were compared, the data from this study strongly
suggested that vaginal C. parapsilosis can be a
pathogen responsible for vulvovaginal complaints.
Symptomatic relief was experienced by 65% of
women who cleared the isolate on follow-up culture.
In those who did not report symptomatic relief at
their follow-up visits, 10/13 had other vulvovaginal
conditions. It is possible that C. parapsilosis was
contributing to their symptoms but that their other
problems prevented complete symptomatic relief.
Alternatively, it may be that C. parapsilosis was an
innocent bystander in those cases where clearance
was not associated with clinical cure. Furthermore,
in women with other vulvovaginal conditions who
did get better, it is possible that their improvement
was not secondary to the disappearance of C.
parapsilosis, but rather to improvement of their other
conditions with further time.
Agatensi and colleagues hypothesized that C.
parapsilosis is a potential vaginal pathogen, in that
isolates demonstrate acid (aspartyl) proteinase activ-
ity [7]. This enzyme is capable of hydrolyzing
mucosal IgA and interfering with the natural vaginal
barrier to infection. Additionally, the isolates cul-
tured from symptomatic subjects demonstrated
signiﬁcantly higher proteinase activity than control
cultures. The only other candidal isolate capable of
signiﬁcant acid proteinase activity is C. albicans,a
known vaginal pathogen. It seems logical that the
proteolytic acitivity shared by both C. parapsilosis and
C. albicans may explain their common behavior as
pathogenic organisms. Additionally, women suffer-
ing with multiple vulvovaginal diagnoses, and with
theoretically compromised integrity of the vaginal
mucosa, may be more susceptible to infection with
C. parapsilosis because of the acid proteinase activity
of the organism. This suggestion is supported by the
observation that several of the women who sponta-
neously cleared C. parapsilosis did so while receiving
non-antimycotic treatment for other vulvovaginal
conditions. Perhaps restoration of healthy vaginal
epithelium diminishes the ability of C. parapsilosis to
infect its host.
Despite its apparent virulent capability in the
vagina, our data also suggest that vaginal infection
with C. parapsilosis is treated and cleared from
subsequent culture relatively easily. In all but 2 cases
in this series, the infection cleared with a single
course of antimycotic therapy. Ot these 2 cases, 1
cleared the isolate with a second antimycotic agent,
and the other cleared the isolate while receiving
steroid treatment for a separate vulvovaginal condi-
tion. Admittedly, there is an inherent treatment bias
that may skew the results toward a relatively high
mycotic response rate, in that all the women received
fairly aggressive treatment regimens. The ﬁnding
that C. parapsilosis seems to clear fairly easily with
antifungal therapy is not too surprising. We did not
obtain in vitro susceptibility testing of our isolates to
various antifungal agents. However, when Lynch and
Sobel evaluated 377 clinical vaginal yeast isolates,
they found that the 26 C. parapsilosis isolates seemed
to have sensitivities which were quite similar to those
of the C. albicans isolates [10]. Interestingly, 6
subjects cleared the isolate without speciﬁc antifun-
gal therapy.
Further study of Candida parapsilosis should
prospectively compare mycotic response with stan-
dard single-dose azole treatment, aggressive multiple
dose regimens, and no treatment. In comparing
these treatment groups, it may become clear that C.
parapsilosis does not demonstrate the inherent azole
resistance displayed by other non-C. albicans species.
The number of cases of spontaneous isolate resolu-
tion suggests that C. parapsilosis may have limited
virulent longevity in the vaginal environment.
In summary, Candida parapsilosis is a signiﬁcant
non-C. albicans vaginal isolate responsible for vulvo-
vaginal complaints. Even when it appears to be a
transient vaginal colonizer, it may be associated with
vulvovaginal symptoms. In symptomatic patients,
antifungal treatment should be expected to achieve
symptomatic cure in a large number of patients.
Properly controlled studies are still necessary to
determine the most efﬁcient antimycotic treatment
regimen. In view of the relative rarity of this
organism, an appropriately powered, randomized
controlled trial is unlikely. However, in cases with a
complicated history of recurrent candidiasis, ex-
tended antifungal treatment with ﬂuconazole,
buconazole, miconazole, or boric acid is reasonable
but may be more aggressive than truly necessary.
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